Press release

Lifecare ASA listed on Euronext Oslo Børs

Bergen, Norway, 22 October 2024: Today, Lifecare ASA (LIFE), a clinical stage medical sensor company developing the next generation Continuous Glucose Monitor (CGM), has its first day of trading at Euronext Oslo Børs.

Reference is made to Lifecare’s stock exchange announcement 21 September 2024, announcing that Oslo Børs approved Lifecare’s transfer from Euronext Growth to Euronext Oslo Børs. Today, Lifecare’s management and board of directors rang the bell to mark the opening of the markets at Oslo Børs.

- Taking the step to the regulated market Euronext Oslo Børs is an important milestone for Lifecare. On behalf of the entire organization, I am very proud that Oslo Børs has assessed and concluded that Lifecare meets the conditions for admission to the main list. We have proven the technology; we have focused on setting up production and we are now approaching our first product. Lifecare is ready for Euronext Oslo Børs, says CEO Joacim Holter at Lifecare ASA.

The company has been listed on Euronext Growth since 2018. In February 2024 the board decided to apply for listing at Euronext Oslo Børs. Just eight months later, the listing has become a reality.

- We have had a rapid development since we entered Euronext Growth six years ago, and our organization has matured as we have prepared the company for Euronext Oslo Børs. Over the past 3-4 years, the company has accelerated in technology, production preparations, organizational development and preparations for the commercialization phase, Holter adds.

Holter mentions that Lifecare has developed from a listed start-up company to an international group with presence in Norway, Germany and England. Lifecare has increased the staff from 2 in 2020 to approximately 35 employees today.

- We have streamlined our administrative operations, balancing cutting-edge technological innovation with future commercialization efforts. I am incredibly proud of the Lifecare team, who have worked tirelessly to bring us to this point. Looking forward, I am excited for the future as we aim to introduce the next generation of CGM-sensors to improve diabetes management for humans and pets, says Holter.

- Diabetes is a pandemic of unprecedented magnitude spiralling out of control, affecting hundreds of millions of people worldwide. Our ambition is to make life easier, better, and more predictable for patients and pets with diabetes. Lifecare is dedicated to developing the next generation of miniaturized and implantable long-term Continuous Glucose Monitors to the market. Now, with the listing at Euronext Oslo Børs, we are making Lifecare more accessible to institutional and international investors, says Holter.

About us
Lifecare ASA is a clinical stage medical sensor company developing technology for sensing and monitoring of various body analytes. Lifecare's main focus is to bring the next generation of Continuous Glucose Monitoring ("CGM") systems to market. Lifecare enables osmotic pressure as sensing principle, combined with the ability to manipulate Nano-granular Tunnelling Resistive sensors ("NTR") on the sensor body for read-out of pressure variations. Lifecare's sensor technology is referred to as "Sencell" and is suitable for identifying and monitoring the occurrence of a wide range of analytes and molecules in the human body and in pets.